Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission

Current HIV/AIDS Reports

Volumn 11, Issue 4, 2014, Pages 447-458

  Haddad, Lisa B ^a   Polis, Chelsea B ^b   Sheth, Anandi N ^a   Brown, Jennifer ^c   Kourtis, Athena P ^d   King, Caroline ^d   Chakraborty, Rana ^a   Ofotokun, Igho ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

AIDS; Contraception; HIV; Hormonal contraception; Transmission

Indexed keywords

CONTRACEPTIVE AGENT; GESTAGEN; GLUCOCORTICOID; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NONOXINOL 9; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONDOM USE; CONTRACEPTION; CONTRACEPTIVE PATCH; FAMILY PLANNING; FEMALE CONDOM; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; OVULATION DETECTION; PUBLIC HEALTH; REVIEW; UTERINE CERVIX CAP; VIRUS CELL INTERACTION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; DISEASE TRANSMISSION; FEMALE; HIV INFECTIONS; INTRAUTERINE CONTRACEPTIVE DEVICE; MALE; PATHOGENICITY; PREGNANCY; PROCEDURES; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME; UTILIZATION;

ANTI-RETROVIRAL AGENTS; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES; MALE; PREGNANCY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84919464828     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0236-6     Document Type: Review

References (145)

1. Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plan. 2010;41(4):241–50.
2. Mavranezouli I. Health economics of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):187–98.
3. Singh S, Darroch JE. Adding it up: costs and benefits of contraceptive services: estimates for 2012. 2012.
4. Wilcher R et al. From effectiveness to impact: contraception as an HIV prevention intervention. Sex Transm Infect. 2008;84 Suppl 2:ii54–60.
5. World Health Organization. Hormonal contraception and HIV technical statement. Geneva: World Health Organization; 2012.
6. The Inter-agency Task Team for Prevention and Treatment of HIV Infection in Pregnant Women, M, and their Children. Preventing HIV and unintended pregnancies: strategic framework 2011–2015. 2012. http://www.unfpa.org/webdav/site/global/shared/documents/publications/2012/PreventingHIV_UnintendedPregnancies_SF2011_2015.pdf.
7. Johnston B et al. Meeting the family planning needs of women living with HIV in US government global health programs. AIDS. 2013;27 Suppl 1:S121–5.
8. World Health Organization. Dissemination and evaluation of the 2014 guidance statement on hormonal contraceptive methods for women at high risk and living with HIV. Geneva: WHO; 2014. This report reviews the most recent evidence and summarizes the current guidelines on the topic from the World Health Organization.
9. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS. 2013;27(5):787–94.
10. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013;13(9):797–808.
11. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS. 2013;27(4):493–505. This is a systematic review of the literature through 2012 evaluating the epidemiological evidence on use of various hormonal contraceptive methods and female-to-male HIV transmission.
12. Polis CB et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception. 2014;90(4):360–90. This is a systematic review of the epidemiological evidence on use of evaluating use of various hormonal contraceptive methods and HIV acquisition in women.
13. Hatcher R et al. Contraceptive technology. 20th ed. New York: Ardent Media; 2011.
14. Adair T. DHS working papers—men’s condom use in higher-risk sex: trends and determinants in five Sub-Saharan countries. Maryland: USAID; 2008.
15. Padian NS et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.
16. Wilkinson D et al. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database Syst Rev. 2002;4:CD003939.
17. Wilkinson D et al. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database Syst Rev. 2002;4:CD003936.
18. Frank-Herrmann P et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007;22(5):1310–9.
19. Trussell J. Contraceptive efficacy. Arch Dermatol. 1995;131(9):1064–8.
20. United Nations. World contraceptive pattern 2013. 2013 [June 21, 2014]. http://www.un.org/en/development/desa/population/publications/pdf/family/worldContraceptivePatternsWallChart2013.pdf.
21. Heffron R et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19–26. This frequently cited paper is a secondary analysis from a large cohort study. The analysis suggested an increased risk of HIV acquisition and transmission to men associated with use of injectable contraception, and increased global attention to this potential risk.
22. Lavreys L et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS. 2004;18(4):695–7.
23. Marx PA et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med. 1996;2(10):1084–9.
24. Kapiga SH et al. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS. 1998;12(1):75–84.
25. Myer L et al. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol. 2007;36(1):166–74.
26. Taneepanichskul S, Phuapradit W, Chaturachinda K. Association of contraceptives and HIV-1 infection in Thai female commercial sex workers. Aust N Z J Obstet Gynaecol. 1997;37(1):86–8.
27. Kiddugavu M et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17(2):233–40.
28. Morrison CS et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21(1):85–95.
29. Morrison CS et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26(4):497–504.
30. Bulterys M et al. Hormonal contraception and incident HIV-1 infection: new insight and continuing challenges. AIDS. 2007;21(1):97–9.
31. Morrison CS. Commentary: hormonal contraception and HIV acquisition—current evidence and ongoing research needs. Int J Epidemiol. 2007;36(1):175–7.
32. Polis CB et al. Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS. 2013;27 Suppl 1:S35–43.
33. Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS. 2012;26(3):375–80.
34. Baeten JM et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS. 2007;21(13):1771–7.
35. Morrison CS et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS. 2010;24(11):1778–81.
36. Heffron R et al. Use of hormonal contraceptives and risk of HIV-1 transmission—authors’ reply. Lancet Infect Dis. 2012;12(8):510–1.
37. Reid SE et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr. 2010;53(5):606–13.
38. Kleinschmidt I et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception. 2007;75(6):461–7.
39. McCoy SI et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS. 2013;27(6):1001–9.
40. Morrison C, et al. Hormonal contraception and HIV infection: results from a large individual participant data meta-analysis. Presented at AIDS 2014, July 20–25, 2014: Melbourne, Australia.
41. Wall K, et al. Weighing 17 years of evidence: does hormonal contraception increase HIV acquisition risk among Zambian women in discordant couples? Presented at AIDS 2014, July 20–25, 2014: Melbourne, Australia.
42. Lutalo T et al. Effects of hormonal contraceptive use on HIV acquisition and transmission among HIV-discordant couples. AIDS. 2013;27 Suppl 1:S27–34.
43. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31(1):79–97. This paper reviews the potential biologic mechanisms from hormones that could affect HIV risk.
44. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Infect. 1998;74(1):11–9.
45. Trunova N et al. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology. 2006;352(1):169–77.
46. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis. 2000;182(3):708–15.
47. Smith SM et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS. 2004;18(12):1637–43.
48. Gorodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women. Menopause. 2007;14(6):1012–9.
49. Gorodeski GI. Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. Endocrinology. 2007;148(1):218–31.
50. Goode D et al. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS ONE. 2014;9(5):e97767.
51. Bahamondes MV, et al. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Contraception, 2014.
52. Mitchell CM, et al. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J Infect Dis, 2014.
53. Kutteh WH, Moldoveanu Z, Mestecky J. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S51–5.
54. White HD et al. Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am J Reprod Immunol. 1997;37(1):30–8.
55. Lu FX et al. Effects of ovarian steroids on immunoglobulin-secreting cell function in healthy women. Clin Diagn Lab Immunol. 2003;10(5):944–9.
56. Cherpes TL et al. Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation. J Immunol. 2008;181(2):969–75.
57. Laskarin G et al. Progesterone directly and indirectly affects perforin expression in cytolytic cells. Am J Reprod Immunol. 1999;42(5):312–20.
58. Scanlan JM et al. Natural killer cell activity is reduced in association with oral contraceptive use. Psychoneuroendocrinology. 1995;20(3):281–7.
59. Yovel G, Shakhar K, Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol. 2001;81(2):254–62.
60. Chandra N et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retrovir. 2013;29(3):592–601.
61. King AE, Critchley HO, Kelly RW. Innate immune defences in the human endometrium. Reprod Biol Endocrinol. 2003;1:116.
62. Ochiel DO et al. Innate immunity in the female reproductive tract: role of sex hormones in regulating uterine epithelial cell protection against pathogens. Curr Womens Health Rev. 2008;4(2):102–17.
63. Fahey JV, Wira CR. Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. J Infect Dis. 2002;185(11):1606–13.
64. Keller MJ et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21(4):467–76.
65. Li A et al. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril. 2008;90(3):872–5.
66. Mugo NR et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25(15):1887–95.
67. Miller L et al. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol. 2000;96(3):431–9.
68. Hayes R et al. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24 Suppl 4:S15–26.
69. Low N et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 2011;8(2):e1000416.
70. McClelland RS et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. J Infect Dis. 2005;191(3):333–8.
71. Morrison CS et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis. 2004;31(9):561–7.
72. Baeten JM et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29.
73. Clemetson DB et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA. 1993;269(22):2860–4.
74. Tanton C et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS ONE. 2011;6(3):e17480.
75. Kreiss J et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis. 1994;170(6):1597–601.
76. Morrison CS et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010;24(4):573–82.
77. Henin Y et al. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women. J Acquir Immune Defic Syndr. 1993;6(1):72–5.
78. Gardella B et al. HIV shedding in cervico-vaginal secretions in pregnant women. Curr HIV Res. 2011;9(5):313–20.
79. Ghanem KG et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis. 2005;191(3):358–66.
80. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946–59.
81. Rotchford K, Strum AW, Wilkinson D. Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis. 2000;27(5):243–8.
82. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305–10.
83. Radzio J et al. Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS. 2014;28(10):1431–9.
84. Africander D et al. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception. 2011;84(4):423–35.
85. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76(7):636–52.
86. Hapgood JP et al. Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol. 2014;71(6):505–12.
87. Govender Y et al. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS ONE. 2014;9(5):e96497.
88. Richardson BA et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS. 1999;13(15):2091–7.
89. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304:809–13.
90. Achilles SL et al. Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol. 2014. doi:10.1016/j.ajog.2014.05.016.
91. Van Damme L et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971–7.
92. Centers for Disease Control and Prevention (CDC). U.S. medical eligibility criteria for contraceptive use. Morbidity and Mortality Weekly Report (MMWR), 2010.
93. Anderson JE, Santelli J, Gilbert BC. Adolescent dual use of condoms and hormonal contraception: trends and correlates 1991-2001. Sex Transm Dis. 2003;30(9):719–22.
94. Greydanus DE, Patel DR, Rimsza ME. Contraception in the adolescent: an update. Pediatrics. 2001;107(3):562–73.
95. Anderson JE, Santelli J, Mugalla C. Changes in HIV-related preventive behavior in the US population: data from national surveys, 1987-2002. J Acquir Immune Defic Syndr. 2003;34(2):195–202. 1999.
96. Crosby RA et al. Correlates of using dual methods for sexually transmitted diseases and pregnancy prevention among high-risk African-American female teens. J Adolesc Health. 2001;28(5):410–4.
97. Sales JM et al. Differences between dual-method and non-dual-method protection use in a sample of young African American women residing in the Southeastern United States. Arch Pediatr Adolesc Med. 2010;164(12):1125–31.
98. MacPhail C et al. Predictors of dual method use for pregnancy and HIV prevention among adolescent South African women. Contraception. 2007;75(5):383–9.
99. Massad LS et al. Contraceptive use among U.S. women with HIV. J Women’s Health. 2007;16(5):657–66. 15409996.
100. Higgins JA et al. Dual method use at last sexual encounter: a nationally representative, episode-level analysis of US men and women. Contraception. 2014;90:399–406.
101. Santelli JS et al. The use of condoms with other contraceptive methods among young men and women. Fam Plan Perspect. 1997;29(6):261–7.
102. Santelli JS et al. Combined use of condoms with other contraceptive methods among inner-city Baltimore women. Fam Plan Perspect. 1995;27(2):74–8.
103. Brown JL et al. Multiple method contraception use among African American adolescents in four US cities. Infect Dis Obstet Gynecol. 2011;2011:765917.
104. Credé S et al. Factors impacting knowledge and use of long acting and permanent contraceptive methods by postpartum HIV positive and negative women in Cape Town, South Africa: a cross-sectional study. BMC Public Health. 2012;12:197.
105. Dhont N et al. Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care. 2009;14(6):420–5.
106. Heffron R et al. A prospective study of contraceptive use among African women in HIV-1 serodiscordant partnerships. Sex Transm Dis. 2010;37(10):621–8.
107. Kikuchi K et al. High rate of unintended pregnancies after knowing of HIV infection among HIV positive women under antiretroviral treatment in Kigali, Rwanda. Biosci Trends. 2011;5(6):255–63.
108. Laher F et al. A qualitative assessment of decisions affecting contraceptive utilization and fertility intentions among HIV-positive women in Soweto, South Africa. AIDS Behav. 2009;13 Suppl 1:47–54.
109. Nduna M, Farlane L. Women living with HIV in South Africa and their concerns about fertility. AIDS Behav. 2009;13 Suppl 1:62–5.
110. Polis CB et al. Trends and correlates of hormonal contraceptive use among HIV-infected women in Rakai, Uganda, 1994-2006. Contraception. 2011;83(6):549–55.
111. Ezeanolue EE et al. Contraception choices in a cohort of HIV+ women in the era of highly active antiretroviral therapy. Contraception. 2011;84(1):94–7.
112. Carrieri MP et al. Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. AIDS Care. 2006;18(7):795–800.
113. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87(3):183–90.
114. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis. 2009;13(5):552–9.
115. Campbell MS et al. HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS ONE. 2009;4(5):e5690.
116. Brenner B et al. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (London, England). 2004;18(12):1653–60.
117. Bouhlal H et al. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol. 2002;169(6):3301–6.
118. Gutsche S et al. Seminal plasma induces mRNA expression of IL-1beta, IL-6 and LIF in endometrial epithelial cells in vitro. Mol Hum Reprod. 2003;9(12):785–91.
119. Sharkey DJ et al. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod. 2007;13(7):491–501.
120. Sharkey DJ et al. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol. 2012;188(5):2445–54.
121. Berlier W et al. Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod. 2006;21(5):1135–42.
122. White HD et al. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol. 1997;158(6):3017–27.
123. Plummer FA. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S5–10.
124. Cu-Uvin S et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14(4):415–21.
125. Kovacs A et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358(9293):1593–601.
126. Cohen MS et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
127. Flynn PM et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-Up. AIDS Res Hum Retrovir. 2007;23(10):1208–14.
128. Murphy DA et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249–55.
129. Murphy DA et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27–40.
130. Roccio M et al. Low-dose combined oral contraceptive and cervicovaginal shedding of human immunodeficiency virus. Contraception. 2011;83(6):564–70.
131. Debiaggi M et al. Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis. 2001;20(2):91–6.
132. Rasheed S. Infectivity and dynamics of HIV type 1 replication in the blood and reproductive tract of HIV type 1-infected women. AIDS Res Hum Retrovir. 1998;14 Suppl 1:S105–18.
133. Donnell D et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092–8.
134. Del Romero J et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205.
135. Neely MN et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(1):38–42.
136. Fiore JR et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS. 2003;17(15):2169–76.
137. Andreoletti L et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naive African women. J Infect Dis. 2003;188(4):549–54.
138. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51(6):725–31.
139. Anton P, Herold BC. HIV transmission: time for translational studies to bridge the gap. Sci Transl Med. 2011;3(77):77ps11.
140. Day S et al. A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;66(4):452–6.
141. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2013 updated 7/31/12; cited 2013 November 14. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
142. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Editor.
143. Centers for Disease Control and Prevention (CDC). Update to CDC’s U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR. 2012;61(24):449–52.
144. Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG. 2012;119(9):1067–73.
145. Butler AR et al. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS. 2013;27(1):105–13.